Background
As the rest of the population, pregnant women living in areas of different malaria endemicity experience varying degrees of exposure to infection, which affects the acquisition of antimalarial immunity and determines the course of disease [
1,
2]. Protective immunity to
Plasmodium falciparum in pregnancy has been suggested to rely mostly on antibodies against VAR2CSA that block adhesion of infected erythrocytes to placental chondroitin sulphate A, and thereby prevent parasite sequestration in the placenta [
3]. Such immune resistance to
P. falciparum, which is acquired after exposure to placental-type parasites, reduces parasite densities below the detection limit of microscopy (i.e. submicroscopic infections) [
4‐
6] and can eventually clear placental infections.
Infected hosts may also tolerate the presence of
P. falciparum by minimising parasite-induced damage without necessarily limiting the infection [
7‐
9]. This type of host defence, not to be confused with immunological tolerance [
7,
10], has been suggested by the frequent observation in malaria endemic areas of individuals, including pregnant women, who harbour levels of parasitaemia in their blood that would commonly be associated with fever in malaria-naïve individuals [
11,
12]. Moreover, the higher risk of life-threatening disease in younger age groups [
13] supports the notion that the ability to modulate host inflammation (anti-disease or clinical immunity) [
14,
15] develops faster than the capacity to restrict parasite growth (anti-parasite immunity). However, other studies do not support the hypothesis that a special clinical immunity exists independently of parasitological immunity [
16], but rather suggest that immunity resulting in decreased parasite densities reduces the severity of symptoms.
Resolving the role of resistance and tolerance could aid the development of host-directed therapies to reduce malaria-induced immunopathology and mitigate malaria disease [
9]. However, quantitative analyses of tolerance to human malaria have been mainly limited to the assessment of peripheral
P. falciparum parasitemia needed to trigger the onset of fever (i.e. pyrogenic threshold) [
14,
15]. Alternative clinical outcomes and analytical frameworks are needed for pregnant women in whom parasitaemia is poorly associated with fever [
17]. Here, we aimed to assess the variations in the clinical impact of
P. falciparum infections and in host defences developed by pregnant women under different malaria transmission intensities. To achieve this, we compared the carriage of submicroscopic infections and antibodies against
P. falciparum antigens as indicators of the level of parasitological immunity [
1]. We assessed the correlation between health outcomes (haemoglobin levels and birthweight) and parasite densities at delivery for summarising tolerance [
8], with a flat slope indicative of tolerance to infection. As immune resistance is strongly influenced by the number of previous pregnancies in areas of stable transmission [
18] and pregnancy outcomes can be affected by the preventive measures used during pregnancy, analyses were adjusted for parity of the pregnant women and the antimalarials received as intermittent preventive treatment during pregnancy (IPTp).
Discussion
Although the importance of tolerance in the context of
P. falciparum infection was suggested early on [
29], the link between such a host defence strategy and malaria disease has been obscured by the difficulties of quantifying the tolerance phenotype. We sought to reduce the complexity of tolerance to a single metric based on the relationship between parasite densities and health outcomes (haemoglobin levels and birthweight) [
8], with a flat slope indicative of tolerance to infection. To assess for variations in the levels of resistance to
P. falciparum among women from the different endemic areas, we used the proportion of submicroscopic infections at delivery and IgG levels against parasite antigens as an indicator of the ability of pregnant women to restrict parasite growth [
1]. Here, we have demonstrated that the lowest levels of immune resistance and tolerance observed among HIV-uninfected Mozambican women, compared to women from Benin, were accompanied by the largest adverse impacts of
P. falciparum infections. Thus, the reduced severity of infections observed in pregnant women from high endemic regions [
1] may not be mediated entirely by an adaptive immune response to the parasite, but also by a tolerance to
P. falciparum, as quantified by the slope of the relationship between parasite densities and haemoglobin levels [
8]. Taken together, these results provide evidence that pregnant women develop exposure-dependent mechanisms to minimise malaria pathology which, in concert with immune resistance, can reduce the adverse impact of
P. falciparum infections.
Variation in resistance to
P. falciparum among HIV-uninfected women from three sub-Saharan African countries was suggested by different proportions of submicroscopic infections. Prevalence of qPCR-detected
P. falciparum infections at delivery ranged from 41% in Benin to 11% in Gabon and 6% in Mozambique. Pregnant women from Benin had the highest proportion of submicroscopic infections at delivery, suggesting an increased capacity to maintain infections at densities bellow the detection limit of microscopy. These observations are in contrast with trends reported showing a significantly higher percentage of infections detected by microscopy in the general population residing in areas of high compared to those in low transmission areas [
30]. These discrepancies may suggest a special dynamic and progression of
P. falciparum infection during pregnancy compared to infections in non-pregnant hosts. In line with this, PfHPR2 levels in plasma, indicative of total parasite biomass [
26], were lower among Beninese than Mozambican women, whereas levels of anti-parasite antibodies, as well as the increase with parity of IgGs against DBL3X from VAR2CSA, were higher in women from Benin than from Mozambique. Overall, these data supports the notion that the acquisition of antimalarial immunity after exposure to
P. falciparum parasites can increase the capacity to resist
P. falciparum growth during subsequent infections in pregnancy.
Variations in tolerance to
P. falciparum were also observed in pregnant women living under contrasting levels of malaria transmission, as indicated by differences in the relationship between haemoglobin levels and increasing parasite burden. In this study, haemoglobin levels at delivery decreased as parasite densities increased in HIV-uninfected women from the lowest transmission setting in Mozambique. By contrast, the haemoglobin level in HIV-uninfected Beninese and Gabonese women were not affected by parasite density, indicating a better tolerance to the infection [
7]. Parasite factors such as the level of resistance to SP, as well as the protective effect of IPTp with SP against adverse birth outcomes that are related to curable sexually transmitted and reproductive tract infections [
31,
32], may affect the clinical impact of infections among pregnant women who received antimalarials as IPTp. However, no relationship was observed between the level of molecular markers of SP resistance in the parasite population based on the frequencies of dihydropteroate synthase (
Pfdhps) K540E mutation [
33,
34] previously reported (>90%
Pfdhps-K540E in Kenya [
33] but < 50% in Mozambique [
35], Gabon [
36] and Benin [
37]) and the outcomes of the study. Moreover, the efficacy of IPTp with SP to clear peripheral parasites and prevent new infections during pregnancy has been suggested to be compromised only in areas with > 90% prevalence of
Pfdhps K540E mutation [
33]. Taken together, these results suggest that immunoregulatory responses that reduce pathogenic inflammation and potentially the risk of anaemia [
38] may be developed by pregnant women exposed to
P. falciparum, as has been suggested for children [
39‐
41].
In absence of HIV infection, the adverse clinical impact of
P. falciparum infections was the highest in pregnant women from the low transmission site in Mozambique, who had the lowest levels of immune resistance and tolerance to
P. falciparum. This adverse impact was observed for microscopic
P. falciparum infections, which were associated with reductions in maternal haemoglobin levels at delivery as well as with increased drops in haemoglobin levels from recruitment to delivery, but not with birthweight. Moreover, placental past/chronic infections among Mozambican women were associated with an increased risk of preterm births, in accordance with previous studies showing a larger impact of infections during pregnancy compared to infections detected only at delivery [
42‐
44]. Such an adverse effect of placental past/chronic infections on the birthweight of newborns was not observed among Beninese or Gabonese women.
P. falciparum microscopic infection in Gabonese women was also associated with an increased drop in haemoglobin levels from recruitment to delivery, although of a lower magnitude than the drop observed in Mozambican women. These data suggest that the malaria-related adverse impact in the health of pregnant women is higher in Gabon than in Benin, but lower than in Mozambique. Such an intermediate severity of the infections in Gabonese women might be explained by the development of tolerance to
P. falciparum (as suggested by the lack of an association between haemoglobin levels with increasing parasite densities) rather than by immune resistance to the infection (as indicated by the similar carriage of submicroscopic infections in Gabonese and Mozambican women). Overall, this evidence suggests that resistance and tolerance to malaria can be acquired after exposure to
P. falciparum parasites in areas of high transmission, and can reduce the detrimental consequences of
P. falciparum infections. Importantly, HIV-infected pregnant women from Kenya and Mozambique did not show any evidence of varying levels of resistance or tolerance, suggesting that the ability to limit the adverse impact of
P. falciparum infection may be reduced when the immune system is suppressed by the viral infection [
45].
This study has some limitations. First,
P. falciparum infection at delivery in women who received IPTp most likely reflect a recently acquired infection. Thus, this study may under-estimate the adverse impact of
P. falciparum infections during pregnancy, as compared to recent reports showing that submicroscopic
P. falciparum infection at inclusion (16.5 weeks) increases the risk of low birth weight for primigravid and premature delivery for multigravid pregnant Beninese women [
6]. Second, other factors apart from anti-parasite immunity may contribute to the carriage of submicroscopic infections, such as the stage of the infection, the chronicity of infections, which is most common among primigravid women without immunity to placental parasites [
46], and the existence of suppressive levels of antimalarial drugs. Third, site-specific differences in the extent of healthcare provided and economic development, as well as other factors than can affect pregnancy outcomes (i.e. haemoglobinopathies), might contribute to variations in the clinical impact of infections among pregnant women from different countries. However, the impact of these differences was minimised by the fact that this study was performed in the context of a clinical trial following standard procedures [
19,
20] and that the analysis was adjusted by potential confounders. Fourth, the immunological analyses were conducted only in a subset of plasma samples available from the women included in the study, which were similar in covariates with the rest of the women. Fifth, analyses were performed by group, rather than at the individual level, assuming uniform exposure and risk among all individuals at each site. Finally, the small prevalence of
P. falciparum infection among HIV-positive women who were receiving co-trimoxazole during pregnancy [
20] may have reduced the power to detect variations in resistance and tolerance to malaria.
Acknowledgments
We are grateful to the women from Benin, Gabon, Kenya and Mozambique participating in the study; the staff of the Hospitals, clinical officers, field supervisors and data manager; Dr Chetan Chitnis for his contribution with the recombinant proteins used in the Luminex-based assays; Laura Puyol, Lázaro Mussacate, Nelito Ernesto José, Ana Rosa Manhiça, Augusto Nhabomba and Chenjerai S. Jairoce for their contribution to the collection and analysis of samples and Jaume Ordi for placental histologies. The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the CDC.